<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="1322">
  <stage>Registered</stage>
  <submitdate>29/05/2006</submitdate>
  <approvaldate>30/05/2006</approvaldate>
  <actrnumber>ACTRN12606000212550</actrnumber>
  <trial_identification>
    <studytitle>The PMI Study</studytitle>
    <scientifictitle>A cohort observational study to assay natriuretic peptide levels in people who have had a Myocardial Infarction (MI) to determine if they are better prognostic indicators of death and all cardiovascular events after acute MI than other indices as well as a better reflection of the left ventricular function as assessed by Radionuclide Ventriculography</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>nil known</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Myocardial infarction</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular</conditioncode1>
      <conditioncode2>Other cardiovascular diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>natriuretic peptide levels 24-96 hours post myocardial infarction and at 3-5 months and 12 months post discharge</interventions>
    <comparator>No comparator.</comparator>
    <control>Uncontrolled</control>
    <interventioncode>None</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Natriuretic peptide levels are better prognostic indicators of death and all cardiovascular events after acute myocardial infarction than other indices</outcome>
      <timepoint>24 - 96 hours post MI and at 3 - 5 months and 12 months post discharge</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Natriuretic peptide levels better reflect left ventricular function.</outcome>
      <timepoint>Assessed by radionuclide ventriculography and/or echocardiography24-96 hours post myocardial infarction and at 3-5 months and 12 months post discharge.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Diagnosis of MI24-96h from symptoms onsetMale or female18-80 years of ageCK =400u/L.andchest pain or other symptoms suggesting myocardial ischaemiaorST elevation of = 1mm in 2 contigous ECG leadsor New pathological Q waves.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>80</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Unable to provide informed consent.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs>Natural history</purposeobs>
    <duration>Longitudinal</duration>
    <selection>Defined population</selection>
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>13/11/1994</anticipatedstartdate>
    <actualstartdate>13/11/1994</actualstartdate>
    <anticipatedenddate />
    <actualenddate>10/06/2001</actualenddate>
    <samplesize>1000</samplesize>
    <actualsamplesize>1000</actualsamplesize>
    <recruitmentstatus>Active, not recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>31/12/2024</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Christchurch</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Government body</primarysponsortype>
    <primarysponsorname>Health Research Council of New Zealand</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>New Zealand</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>Health Research Council of New Zealand</fundingname>
      <fundingaddress />
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Charities/Societies/Foundations</sponsortype>
      <sponsorname>National Heart Foundation of New Zealand</sponsorname>
      <sponsoraddress />
      <sponsorcountry>New Zealand</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is an cohort observational study to assess whether natriuretic peptide levels are better prognostic indicators of death and all cardiovascular events after acute myocardial infarction than other indices, and also better reflect left ventricular function as assessed by radionuclide ventriculography and/or echocardiography.
Measurements will be carried out, 
within 24-96 hours of onset of chest pain and again at 3-5 months and 12 months after acute infarction.
Clinical History will be recorded for 5 years</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Christchurch</ethicname>
      <ethicaddress />
      <ethicapprovaldate>30/09/1994</ethicapprovaldate>
      <hrec>97/784</hrec>
      <ethicsubmitdate />
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>Professor Mark Richards</name>
      <address>Department of Medicine
Christchurch School of Medicine and Health Sciences
PO Box 4345
Christchurch</address>
      <phone>+64 3 3641116</phone>
      <fax>+64 3 3641115</fax>
      <email>mark.richards@cdhb.govt.nz</email>
      <country>New Zealand</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Ms</title>
      <name>Lorraine Skelton</name>
      <address>Department of Medicine
Christchurch School of Medicine and Health Sciences
PO Box 4345
Christchurch</address>
      <phone>+64 3 3641063</phone>
      <fax>+64 3 3641115</fax>
      <email>lorraine.skelton@cdhb.govt.nz</email>
      <country>New Zealand</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Mark Richards</name>
      <address>Department of Medicine. University of Otago, Christchurch. PO Box 4345 Christchurch. 8140. New Zealand</address>
      <phone>+6433641063</phone>
      <fax>+6433641115</fax>
      <email>mark.richards@cdhb.health.nz</email>
      <country>New Zealand</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>